- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02750137
Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop
Ametop - Friend or Foe A Prospective Observational Study of the Incidence of Adverse Reactions With Ametop
Study Overview
Detailed Description
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. After several critical incidences of adverse reactions that occurred with its application, a departmental audit was carried out to look at the incidence and severity reactions with its application as well as its outcome on intravenous cannulation. The findings of the departmental audit showed that the incidence of adverse reactions seemed to occur more commonly compared to other studies.
A prospective observational study was carried out to look at the incidence and severity of skin reactions following routine clinical application of Ametop.
This study aims to achieve the following:
- Investigate the incidence and severity of adverse skin reactions following topical application of Ametop prior to intravenous cannulation
- Assess the success rate of intravenous cannulation
- Identify the possible risk factors associated with adverse skin reaction.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All paediatric patients presenting for surgery from August 2014 to May 2015 who have had Ametop applied prior to intravenous cannulation.
Exclusion Criteria:
- Any patient who did not have Ametop applied or have an intravenous cannula in situ.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of skin reactions with Ametop
Time Frame: October 2014 to May 2015
|
looking at the incidence of skin reactions with Ametop - normal, simple erythema, raised erythema, itch, pallor
|
October 2014 to May 2015
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk factors associated with incidence of skin reactions
Time Frame: October 2014 to May 2015
|
Looking at possible factors associated with skin reactions - race, duration of application, history of atopy
|
October 2014 to May 2015
|
Collaborators and Investigators
Investigators
- Principal Investigator: Angela YJ Tan, MMed, KK Women's and Children's Hospital
Publications and helpful links
General Publications
- Browne J, Awad I, Plant R, McAdoo J, Shorten G. Topical amethocaine (Ametop) is superior to EMLA for intravenous cannulation. Eutectic mixture of local anesthetics. Can J Anaesth. 1999 Nov;46(11):1014-8. doi: 10.1007/BF03013194.
- Arrowsmith J, Campbell C. A comparison of local anaesthetics for venepuncture. Arch Dis Child. 2000 Apr;82(4):309-10. doi: 10.1136/adc.82.4.309.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/2158
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Drug Event
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedAdverse Drug Event, Potential Adverse Drug Event, and Quality MeasuresUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Vancouver Coastal Health; Ministry...Not yet recruitingAdverse Drug Event | Adverse Drug Reaction
-
University of PittsburghRANDCompletedAdverse Drug EventsUnited States
-
US Department of Veterans AffairsCompletedAdverse Drug EventsUnited States
-
Westview Physician CollaborativeCompletedAdverse Drug EventsCanada
-
Ottawa Hospital Research InstituteMcGill University; Canadian Institutes of Health Research (CIHR)CompletedAdverse Drug EventsCanada
-
Intermountain Health Care, Inc.Completed
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); National Institute on Aging (NIA)Completed
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Baycrest Centre for Geriatric...WithdrawnAdverse Drug Events
-
Indiana UniversityBrigham and Women's HospitalCompleted
Clinical Trials on Tetracaine
-
Cetylite IndustriesCompletedNo Disease State or ConditionUnited States
-
Wenzhou Medical UniversityCompleted
-
New York Presbyterian Brooklyn Methodist HospitalUnknown
-
Fraser HealthCompleted
-
Cetylite IndustriesCompleted
-
Jazz PharmaceuticalsWithdrawnHealthy | AnesthesiaUnited Kingdom
-
INTEGRIS Southwest Medical CenterCompleted
-
West China HospitalUnknownCatheter Site DiscomfortChina
-
Sintetica SACompletedCataractItaly, Slovakia, Spain